Recent News

• 06.13.2025 - Beam Therapeutics Investor Webcast – EHA 2025
• 06.13.2025 - Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress
• 06.03.2025 - Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease
• 05.29.2025 - Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
• 05.29.2025 - Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
• 05.20.2025 - 2025 RBC Capital Markets Global Healthcare Conference
• 05.20.2025 - 2025 RBC Capital Markets Global Healthcare Conference
• 05.14.2025 - Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress
• 05.13.2025 - Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference
• 05.13.2025 - Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference

Recent Filings

• 06.06.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.06.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.06.2025 - 8-K Current report
• 06.06.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.06.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.06.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.06.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.06.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.15.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.13.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors